Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569 | 0.70 | NPC1 (0.45) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL3435529 | 0.70 | CYP11B1 (0.38) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL1564969 | 0.69 | CHEK1 (0.44) | — | |
| SCHEMBL910452 | 0.68 | CRBN (0.39) | — | |
| SCHEMBL859012 | 0.68 | MMP12 (0.38) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL18307151 | 0.68 | MMP12 (0.38) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL3082129 | 0.68 | ALDH1A1 (0.38) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL75634 | 0.67 | MMP12 (0.47) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL17095009 | 0.66 | PARP1 (0.37) | MMP12NR3C2ALDH1A1MAPTPARP1 | |
| SCHEMBL592791 | 0.66 | NR3C2 (0.47) | MMP12NR3C2ALDH1A1MAPTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0462813-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-10-25 | — | — | EP | claimed |
| US-5373007-A | Lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-12-13 | — | — | US | claimed |
| EP-0462813-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | claimed |
| US-20220218705-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11220496-B2 | Compounds and method for treating autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200087293-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-0462813-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-10-25 | — | — | EP | disclosed |
| US-5373007-A | Lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-12-13 | — | — | US | disclosed |
| US-5321025-A | Inhibitors of 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-14 | — | — | US | disclosed |
| US-5217969-A | Antiinflammatory, antiulcer agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0462813-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220496-B2 | Compounds and method for treating autoimmune diseases | NR1H2, CNR2, CNR1 | MMP12 3138/4885NR3C2 52/4885ALDH1A1 2040/4885 |
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MMP12 2404/4885NR3C2 2862/4885ALDH1A1 3686/4885 |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MMP12 2366/4885NR3C2 2869/4885ALDH1A1 3988/4885 |
| US-20220218705-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | NR1H2, CNR2, CNR1 | MMP12 3138/4885NR3C2 52/4885ALDH1A1 2040/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MMP12 2366/4885NR3C2 2869/4885ALDH1A1 3988/4885 |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MMP12 2368/4885NR3C2 3650/4885ALDH1A1 4036/4885 |
| US-20200087293-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | NR1H2, CNR2, CNR1 | MMP12 3138/4885NR3C2 52/4885ALDH1A1 2040/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | MMP12 2404/4885NR3C2 2862/4885ALDH1A1 3686/4885 |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | FLI1, API5, MAVS | MMP12 2136/4885NR3C2 4820/4885ALDH1A1 3269/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | MMP12 2404/4885NR3C2 2862/4885ALDH1A1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.